Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 8 findings · 2 reviews · Airways

No studies found 0 · 0%GRADE not reported 1 · 12.5%Very low 0 · 0%Low 4 · 50%Moderate 3 · 37.5%High 0 · 0%

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).

2 findings from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

1 finding from 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice

Non‐fatal serious adverse events · adults with asthma not well controlled on ICS

160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).

1 finding from 1 review